“…Early activation events following cell incubation with and without either phytohemagglutinin or autologous tumor tissue, as measured by FDA staining, reflect differences in intracellular conditions related to the enzymatic activity, cell size, cell surface status and cytoplasmic membrane permeability, as well as cell type, cell cycle stage, etc. [17][18][19][20][21][22]. Moreover, recently, we have shown that, in BC patients, the enzymatic activity of peripheral blood cells interacting with autologous tumor antigens, differ remarkably from the enzymatic reactions in healthy individuals.…”